Quantcast

Latest Gynecologic Oncology Group Stories

2011-02-28 11:00:00

Selected abstract points to efficacy of treatment guidelines and need for improved practices CHICAGO, Feb. 28, 2011 /PRNewswire-USNewswire/ -- In their continuing quest to eradicate women's cancers, gynecologic oncologists are developing new approaches to treatment, diagnosis and prevention of these diseases. An outstanding assortment of new research will be on display in Orlando, March 6 - 9, 2011, during the Society of Gynecologic Oncologists' (SGO) 42nd Annual Meeting on Women's Cancer,...

2011-02-11 22:07:30

A small proportion of adult cancer patients participate in clinical trials in part due to a low level of physician referrals, according to an online study published Feb. 11 in The Journal of the National Cancer Institute. Although more than 8000 clinical trials are accepting participants, according to the National Cancer Institute (NCI), only an estimated 2%ð”Æ’“š% of newly diagnosed cancer patients participate in them. Prior studies suggest that most...

2011-02-10 00:24:08

Research by the American Academy of Family Physicians demonstrates that vulvar cancer occurs most frequently in women age 65 to 75 years of age. Thirty percent of patients with vulvar cancer are age 70 or older, and the rate increases with age, reaching a peak of 20 per 100,000 women by 75 years of age. A team of researchers headed by Ashley Stuckey, MD, and Don Dizon, MD, of the Program in Women's Oncology at Women & Infants Hospital of Rhode Island, recently presented research to the...

2011-01-24 10:00:00

CHICAGO, Jan. 24, 2011 /PRNewswire-USNewswire/ -- The Society of Gynecologic Oncologists (SGO) will host its 42nd Annual Meeting on Women's Cancer March 6-9, 2011, at the Hilton Bonnet Creek & Waldorf Astoria Orlando in Orlando, Florida. This year's meeting will feature 278 scientific presentations in addition to lectures, workshops, symposia and postgraduate courses that focus on emerging science, clinical trials and treatment advances for physicians and health care professionals in...

2010-12-13 07:00:00

HUNTSVILLE, Ala., Dec. 13, 2010 /PRNewswire/ -- EGEN, Inc. today announced that the first Phase II clinical trial utilizing EGEN-001 for the treatment of recurrent ovarian cancer is now open for enrollment. The trial is sponsored by the Gynecologic Oncology Group (GOG) under an agreement between the GOG and EGEN, Inc., and is being conducted by a network of researchers led by the GOG at member institutions. The University of Alabama at Birmingham (UAB) Hospital is the first member...

2010-12-01 06:30:00

CALGARY, Dec. 1 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today the start of enrollment in a randomized Phase II ovarian cancer study. The Gynecologic Oncology Group (GOG) is conducting the randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN((R)) in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H). The study is being sponsored by the Cancer Therapy...

2010-11-10 00:00:42

Women's Oncology Research & Dialogue has lanched a new website to inform women about ovarian, uterine, cervical and all gynecologic cancers at wordoncancer.org. Indianapolis, IN (PRWEB) November 9, 2010 On November 9, 2010 Women's Oncology Research & Dialogue launched their new website at http://www.wordoncancer.org. WORD was founded with the mission of spreading awareness as well as offering insight and education on gynecologic cancers to the world. Founded by two gynecologic...

2010-09-02 06:30:00

TORONTO, Sept. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN(R) in patients with persistent or recurrent, ovarian, fallopian tube or primary peritoneal cancer (GOG186H). The study has been approved and will be sponsored by the Cancer Therapy Evaluation Program, Division of Cancer...

2010-08-04 11:51:00

IRVINE, Calif., Aug. 4 /PRNewswire/ -- OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, is pleased to announce their partnership with The Gynecologic Oncology Group (GOG) through the Industry Collaboration Team (ICT) program. By becoming a member of the ICT, OvaGene Oncology demonstrates its commitment to building a strong partnership with the GOG research groups, namely...

2010-07-12 13:27:00

IRVINE, Calif., July 12 /PRNewswire/ -- OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, announced today that it has completed license agreements with key Norwegian cancer researchers. The agreements allow OvaGene to validate two new promising genomic technologies with the intention of developing these into clinical laboratory tests. Validation studies and the subsequent...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'